ASX August 2026 Stocks Estimated To Be Trading Below Intrinsic Value
As the Australian market looks to start the week on a positive note, buoyed by encouraging movements on Wall Street and a resilient commodities sector, investors are keenly observing opportunities for growth amidst fluctuating economic indicators like unemployment rates. In this environment, identifying stocks trading below their intrinsic value can offer potential advantages, as these investments may provide room for appreciation when market confidence is bolstered by favorable global and local economic trends.
Top 10 Undervalued Stocks Based On Cash Flows In Australia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Telix Pharmaceuticals (ASX:TLX) | A$16.16 | A$27.94 | 42.2% |
| Superloop (ASX:SLC) | A$2.97 | A$5.61 | 47% |
| ReadyTech Holdings (ASX:RDY) | A$1.565 | A$2.77 | 43.6% |
| PolyNovo (ASX:PNV) | A$1.045 | A$1.96 | 46.8% |
| Mesoblast (ASX:MSB) | A$2.35 | A$4.19 | 44% |
| Inghams Group (ASX:ING) | A$2.07 | A$3.75 | 44.8% |
| Elsight (ASX:ELS) | A$5.54 | A$10.79 | 48.7% |
| Cogstate (ASX:CGS) | A$3.04 | A$5.34 | 43.1% |
| Bellevue Gold (ASX:BGL) | A$1.70 | A$3.32 | 48.8% |
| Aroa Biosurgery (ASX:ARX) | A$0.575 | A$0.99 | 41.9% |
We'll examine a selection from our screener results.
Superloop (ASX:SLC)
Overview: Superloop Limited operates as a telecommunications and internet service provider in Australia, with a market cap of A$1.53 billion.
Operations: The company generates revenue from three primary segments: Business (A$113.39 million), Consumer (A$463.19 million), and Wholesale (A$90.12 million).
Estimated Discount To Fair Value: 47%
Superloop is trading at A$2.97, significantly below its estimated future cash flow value of A$5.61, suggesting it may be undervalued based on discounted cash flow analysis. The company reported a substantial increase in net income to A$17.53 million for the year ended June 30, 2026, from A$1.21 million the previous year. Despite insider selling and a forecasted low return on equity of 14.7%, analysts expect earnings growth of 29.3% annually over the next three years.
- Our growth report here indicates Superloop may be poised for an improving outlook.
- Click to explore a detailed breakdown of our findings in Superloop's balance sheet health report.
Tasmea (ASX:TEA)
Overview: Tasmea Limited offers shutdown, maintenance, emergency breakdown, and capital upgrade services in Australia with a market cap of A$2.46 billion.
Operations: The company's revenue segments consist of Civil (A$128.09 million), Electrical (A$266.63 million), Mechanical (A$146.84 million), and Water & Fluid services (A$86.57 million).
Estimated Discount To Fair Value: 24.4%
Tasmea, trading at A$9.42, is valued below its estimated future cash flow value of A$12.46, indicating it may be undervalued based on discounted cash flow analysis. Earnings have grown 37.4% annually over five years and are expected to grow 32% per year, outpacing the Australian market's average growth rate. Recent strategic moves include acquisitions of JPS Group and Maxim Group, alongside a special dividend declaration reflecting strong financial health and strategic confidence.
- The growth report we've compiled suggests that Tasmea's future prospects could be on the up.
- Click here to discover the nuances of Tasmea with our detailed financial health report.
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$5.49 billion.
Operations: Telix Pharmaceuticals generates revenue through its Precision Medicine segment, which accounts for $704.73 million, and its Manufacturing Solutions segment, contributing $277.07 million.
Estimated Discount To Fair Value: 42.2%
Telix Pharmaceuticals, trading at A$16.16, is priced significantly below its estimated future cash flow value of A$27.94, suggesting potential undervaluation based on discounted cash flow analysis. Despite a low forecasted Return on Equity of 14.8%, Telix's earnings are expected to grow substantially at 41.8% annually over the next three years. Recent earnings reports show a strong turnaround with net income reaching US$38.33 million from a previous net loss, highlighting improving financial performance and operational momentum.
- Our comprehensive growth report raises the possibility that Telix Pharmaceuticals is poised for substantial financial growth.
- Dive into the specifics of Telix Pharmaceuticals here with our thorough financial health report.
Next Steps
- Access the full spectrum of 44 Undervalued ASX Stocks Based On Cash Flows by clicking on this link.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com